🇺🇸 FDA
Pipeline program

Idursulfase

HGT-ELA-038

Approved mab completed

Quick answer

Idursulfase for Hunter Syndrome is a Approved program (mab) at TAKEDA PHARMACEUTICAL CO LTD with 2 ClinicalTrials.gov record(s).

Program details

Company
TAKEDA PHARMACEUTICAL CO LTD
Indication
Hunter Syndrome
Phase
Approved
Modality
mab
Status
completed

Clinical trials